← Back to Clinical Trials
Recruiting NCT05920824

NCT05920824 Atrial Functional Mitral Regurgitation and Tricuspid Regurgitation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05920824
Status Recruiting
Phase
Sponsor Barts & The London NHS Trust
Condition Atrial Fibrillation
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2023-08-23
Primary Completion 2027-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Echocardiogram

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2023-08-23 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A prospective, observational cohort study designed to identify clinical phenotypes and evaluate predictors \& outcomes of functional mitral and tricuspid valve regurgitation in patients with atrial fibrillation. Participant will under go: * Baseline echocardiography * Cpex Echocardiography * Blood test: BNP * 1 year follow up Echocardiography Participants will be stratified into three subgroups: * Atrial Functional MR * Atrial Functional TR * Mixed MR \& TR

Eligibility Criteria

Inclusion Criteria: * Informed consent * Age of 18 years or older * Atrial fibrillation * Moderate or severe atrial valve disease * Adequate 2D echocardiography views including parasternal long axis, short axis, apical two chamber, apical three chamber and four chamber. Exclusion Criteria: * Unwilling or unable to give consent * Left ventricular impairment (ejection fraction \< 50%). * Primary/organic valve disease

Contact & Investigator

Central Contact

Jawza Aldakhil

✉ Jawza@outlook.sa

📞 00447899770693

Principal Investigator

Sanjeev bhattacharyya

PRINCIPAL INVESTIGATOR

Barts & The London NHS Trust

Frequently Asked Questions

Who can join the NCT05920824 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05920824 currently recruiting?

Yes, NCT05920824 is actively recruiting participants. Contact the research team at Jawza@outlook.sa for enrollment information.

Where is the NCT05920824 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT05920824 clinical trial?

NCT05920824 is sponsored by Barts & The London NHS Trust. The principal investigator is Sanjeev bhattacharyya at Barts & The London NHS Trust. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology